Domestic and international legal regulations governing pharmaceuticals and cosmetics
First written in FY2016. 6 of 9 entries say "Restated". Latest entry: FY2022.
The whole theme swung hardest in 2022: 3 of 16 companies on the "Worse" side.
17 other companies' latest entry also says "Restated".
- FY2022RestatedAnnual report
「The pharmaceutical and cosmetics industries in which the Group operates are subject to legal regulations under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices and other legislation, as well as local regulations when the final sales destination is overseas.」
Amendments to domestic and international pharmaceutical and cosmetics regulations, and changes in applicable standards, continue to be identified as risks. - FY2021RestatedAnnual report
「The pharmaceutical and cosmetics industries in which the Group operates are subject to legal regulations under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices and other legislation, as well as local regulations when the final sales destination is overseas.」
Amendments to domestic and international pharmaceutical and cosmetics regulations, and changes in applicable standards, continue to be identified as risks. - FY2020MaterialisedAnnual report
「Partly due to higher costs and other expenses related to compliance with new pharmaceutical regulations, operating profit declined 45.1% from the previous fiscal year to ¥140 million.」
Compliance with new pharmaceutical regulations affected full-year results through higher costs, and テプニエ社's operating profit declined 45.1% from the previous fiscal year. - FY2020-Q3MaterialisedAnnual report
「Partly due to higher costs and other expenses related to compliance with new pharmaceutical regulations, operating profit declined 17.0% year on year to ¥88 million.」
Compliance with new pharmaceutical regulations affected テプニエ社's operating profit through higher costs. In the risk section itself, the company states that there have been no material changes in business and other risks. - FY2020-Q2RestatedAnnual report
「Although Japan's cosmetics market shows some fluidity in the outlook for the market environment, including the impact of the implementation of China's E-Commerce Law, US-China trade friction and the depreciation of the Chinese yuan, inbound spending by visitors to Japan appears to remain firm.」
The company refers to fluidity in the market environment, including regulatory and institutional factors such as the implementation of China's E-Commerce Law, but states that there have been no material changes in business and other risks. - FY2020-Q1RestatedAnnual report
「In Japan's cosmetics market, inbound spending by visitors to Japan appears to remain firm, but the market environment also shows some fluidity, as the cosmetics industry is discussing the potential impact of the implementation of China's E-Commerce Law.」
The company refers to fluidity in the cosmetics market environment, including the impact of China's E-Commerce Law. It states that there have been no material changes in business and other risks. - FY2018RestatedAnnual report
「The pharmaceutical and cosmetics industries in which the Group operates are subject to legal regulations under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices and other legislation, as well as local regulations when the final sales destination is overseas.」
Amendments to domestic and international pharmaceutical and cosmetics regulations, and changes in applicable standards, continue to be identified as risks. - FY2017RestatedAnnual report
「The pharmaceutical and cosmetics industries in which the Group operates are subject to legal regulations under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices and other legislation, as well as local regulations when the final sales destination is overseas.」
Amendments to domestic and international pharmaceutical and cosmetics regulations, and changes in applicable standards, continue to be identified as risks. - FY2016First statedAnnual report
「The pharmaceutical and cosmetics industries in which the Group operates are subject to legal regulations, including the Pharmaceuticals and Medical Devices Act and, where the final sales destination is overseas, local regulations. Amendments to these regulations or changes in applicable standards may affect the Group’s performance and financial position.」
Amendments to domestic laws and regulations applicable in overseas markets, as well as changes in applicable standards, are identified as factors that may affect performance.